GlassScriptPhysician profile
Hunter Daniels
NPI 1215424643
$4,131.14
in general payments reported to CMS, 2019-2025
30 companies · $930 in 2025
The $930 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.04 · 2020: $13.70 · 2021: $670 · 2022: $958 · 2023: $779 · 2024: $724 · 2025: $930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,333 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,332.93 |
| Education | $100.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $637.10 | 2021-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $420.61 | 2021-2025 | Lifevest |
| Boston Scientific Corporation | $384.87 | 2022-2025 | Lux-Dx Insertable Cardiac Monitor, Mylux Patient Kit With Mobile Device, Fineline II Sterox |
| Abiomed | $306.42 | 2022-2023 | Impella |
| Pfizer INC. | $260.18 | 2019-2025 | |
| Stryker Corporation | $235.99 | 2025 | Flowtriever, Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Medtronic, INC. | $233.34 | 2022-2025 | Hawkone, Cobalt Dr Mri Surescan, In.Pact Admiral |
| Abbott Laboratories | $194.62 | 2023-2025 | Ensite, Aveir, Cardiomems |
| Inari Medical, INC. | $168.70 | 2022-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Philips North America LLC | $160.16 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $153.66 | 2021-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $129.52 | 2019-2025 | |
| Asahi Intecc USA, INC. | $123.00 | 2025 | Asahi Coronary Wires |
| E.R. Squibb & Sons, L.L.C. | $121.31 | 2022-2024 | Camzyos |
| Irhythm Technologies, INC. | $117.75 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $82.48 | 2022-2023 | Optimizer |
| Livanova USA, INC. | $71.18 | 2022-2023 | Tandemlife |
| Janssen Pharmaceuticals, INC | $55.65 | 2022-2023 | Xarelto |
| Penumbra, INC. | $43.45 | 2023 | Indigo System |
| Bayer Healthcare Pharmaceuticals INC. | $35.26 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $34.58 | 2024-2025 | Verquvo |
| Edwards Lifesciences Corporation | $34.07 | 2024 | Sapien 3 Ultra Resilia |
| Actelion Pharmaceuticals US, INC. | $20.42 | 2023 | Uptravi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.01 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $16.67 | 2024 | Arcalyst |
| Amgen INC. | $15.53 | 2025 | Repatha |
| Shockwave Medical, INC | $13.73 | 2025 | |
| Medtronic Vascular, INC. | $13.70 | 2020 | |
| Chiesi USA, INC. | $13.63 | 2024 | Juxtapid |
| Alnylam Pharmaceuticals INC. | $13.55 | 2025 | Amvuttra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hunter Daniels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.